
GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial for Manganese MRI Contrast Agent
GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial of Manganese-Based MRI Contrast Agent Under FDA Fast Track Status, Advancing Imaging Innovation Pipeline GE HealthCare has announced a major…












